A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
Summary
- Eligibility
- for people ages 18-100 (full criteria)
- Location
- at UCLA UCSD
- Dates
- study startedestimated completion
- Principal Investigator
- by Srila Gopal (ucsd)Sarah Tomassetti (ucla)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientists at UC Cancer
- Srila Gopal (ucsd)
- Sarah Tomassetti (ucla)
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Rigel Pharmaceuticals
- ID
- NCT03764618
- Phase
- Phase 3
- Study Type
- Interventional
- Last Updated